PLX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 16:00):

Stats
Today's Volume	413 234
Average Volume	347 464
Market Cap	82.55M
EPS	$0 ( 2024-03-14 )
Next earnings date	( $-0.0200 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	12.56
ATR14	$0.00700 (0.62%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Bashan Dror	Buy	263 960	Common Stock
2023-10-19	Bashan Dror	Buy	16 129	Common Stock
2023-10-19	Bashan Dror	Buy	48 387	Common Stock
2023-09-29	Boudes Pol F	Buy	61 676	Stock Options (Right to Buy)
2023-09-29	Melincoff Gwen A	Buy	61 676	Stock Options (Right to Buy)

INSIDER POWER
100.00
Last 87 transactions
Buy: 22 496 164 \| Sell: 34 117 800

Volume Correlation

Long: -0.28 (neutral)

Short: -0.05 (neutral)

Signal:(68.961) Neutral

Protalix Biotherapeutics Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Protalix Biotherapeutics Correlation - Currency/Commodity

-0.29
( neutral )

-0.64
( weak negative )

0.00
( neutral )

-0.76
( moderate negative )

Protalix Biotherapeutics Financials

Annual	2023
Revenue:	$65.49M
Gross Profit:	$42.51M (64.91 %)
EPS:	$0.120

Q4	2023
Revenue:	$10.49M
Gross Profit:	$1.63M (15.54 %)
EPS:	$-0.0828

Q3	2023
Revenue:	$10.35M
Gross Profit:	$5.45M (52.70 %)
EPS:	$-0.0256

Q2	2023
Revenue:	$35.08M
Gross Profit:	$28.93M (82.47 %)
EPS:	$0.290

Financial Reports:

No articles found.

Protalix Biotherapeutics

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.